Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Medicine / Institutionen för medicin >
Doctoral Theses / Doktorsavhandlingar Institutionen för medicin >

Diffuse large B-cell lymphoma - proteomic and metabolomic studies on prognosis and treatment failure

Please use this identifier to cite or link to this item:

Files in This Item:

File Description SizeFormat
gupea_2077_56918_3.pdfThesis frame17349KbAdobe PDF
gupea_2077_56918_4.pdfAbstract107KbAdobe PDF
gupea_2077_56918_5.pdfCover4738KbAdobe PDF
Title: Diffuse large B-cell lymphoma - proteomic and metabolomic studies on prognosis and treatment failure
Authors: Stenson, Martin
Issue Date: 5-Nov-2018
University: University of Gothenburg. Sahlgrenska Academy
Institution: Inst of Medicine. Department of Internal Medicine and Clinical Nutrition
Parts of work: Ruetschi U, Stenson M, Hasselblom S, Nilsson-Ehle H, Hansson U, Fagman H, et al. SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. International journal of proteomics. 2015;2015:841769,

Stenson M, Pedersen A, Hasselblom S, Nilsson-Ehle H, Karlsson BG, Pinto R, et al. Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study. Leuk Lymphoma. 2016:1-9,

Bram Ednersson S, Stenson M, Stern M, Enblad G, Fagman H, Nilsson-Ehle H, et al. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. Br J Haematol. 2018,

Date of Defence: 2018-11-23
Disputation: Fredagen den 23 november 2018, kl. 9.00, Patologens Föreläsningssal, Sahlgrenska, Ehrenströmsgatan 1, Göteborg.
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: DLBCL
Abstract: Abstract Background and aim: Every year almost 600 patients in Sweden are diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, and with immunochemotherapy, approximately 60 % are cured. Yet, for patients with primary refractory disease or early relapse, the prognosis is very poor. Despite advances in molecular subclassification of DLBCL, the major tool used to risk stratify patients is the clinically based International Prognostic Index (IPI). However, there is still ... more
ISBN: 978-91-7833-153-6
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för medicin



© Göteborgs universitet 2011